Seeking Alpha

Novavax's (NVAX) vaccine for respiratory syncytial virus (RSV), which causes respiratory...

Novavax's (NVAX) vaccine for respiratory syncytial virus (RSV), which causes respiratory tract infections, produced encouraging results in preclinical studies, inducing anti-RSV antibodies in vitro and cutting infectious RSV in a cotton rat challenge model. In clinical and preclinical studies, antibodies were generated at concentrations "significantly above that found to be protective in both humans and cottons rats." The vaccine is in Phase I and Phase II trials. (PR)
Comments (1)
  • Bullnanke
    , contributor
    Comments (6) | Send Message
     
    Very Encouraging!!!!!
    18 Mar 2013, 11:59 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|